<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38317320</article-id><article-id pub-id-type="pmc">PMC467025</article-id>
<article-id pub-id-type="publisher-id">IJO-72-521</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_2011_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative results of use and switching of anti-TNF-alpha agents in adult Beh&#x000e7;et&#x02019;s uveitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mesen</surname><given-names>Selma</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Ozer</surname><given-names>Muhammet D</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Batur</surname><given-names>Muhammed</given-names></name><xref rid="aff3" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1">Turkoglu Dr. Kemal Beyazit State Hospital Eye Clinic, T&#x000fc;rko&#x0011f;lu, Kahramanmara&#x0015f;, &#x00130;stanbul</aff><aff id="aff2"><label>1</label>Gaziosmanpa&#x0015f;a Hospital Ophthalmology Department, Yeni Y&#x000fc;zy&#x00131;l University, Zeytinburnu, &#x00130;stanbul</aff><aff id="aff3"><label>2</label>Faculty of Medicine, Ophthalmology Department, Van Yuzuncu Yil University, Tu&#x0015f;ba, Van, T&#x000fc;rkiye</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Selma Mesen, Turkoglu Dr. Kemal Beyazit State Hospital Eye Clinic Turkoglu, Kahramanmaras TR 46800, T&#x000fc;rkiye. E-mail: <email xlink:href="drselmamesen@gmail.com">drselmamesen@gmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>2</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S521</fpage><lpage>S528</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>05</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>This study was planned to compare the clinical results and optical coherence tomography (OCT) data of patients who underwent adalimumab (ADA), infliximab (IFX) and switched protocols between these two methods in cases of Beh&#x000e7;et&#x02019;s associated uveitis (BAU).</p></sec><sec id="st2"><title>Methods:</title><p>The patients with BAU who were treated with anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents for at least one year were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA), the central macular thickness (CMT), and the subfoveal choroidal thickness (SFCT) of the patients at the last visit.</p></sec><sec id="st3"><title>Results:</title><p>After a mean follow-up of 16.60 months, the rate of active inflammation decreased from 63.6% to 15.1%. Mean BCVA increased, mean CMT and mean SFCT decreased significantly at the last visit (<italic toggle="yes">P</italic> &#x0003c; 0.001, <italic toggle="yes">P</italic> &#x0003c; 0.001, respectively).</p></sec><sec id="st4"><title>Conclusion:</title><p>Anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment and switching protocols between these two agents effectively and safely control intraocular inflammation in BAU patients.</p></sec></abstract><kwd-group><kwd>Anti-TNF-alpha</kwd><kwd>Beh&#x000e7;et&#x02019;s disease</kwd><kwd>biologic agent</kwd><kwd>choroidal thickness</kwd><kwd>intraocular inflammation</kwd><kwd>switched</kwd></kwd-group></article-meta></front><body><p>Beh&#x000e7;et&#x02019;s disease (BD), first described by Turkish dermatologist Hulusi Beh&#x000e7;et in 1937, is a chronic, idiopathic, and multisystemic disease characterized by oral and genital ulcers and ocular and skin lesions; it progresses with recurrent episodes of inflammation.[<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref>] BD is common, especially in the Mediterranean region, the Middle East, and Far East countries along the Silk Road, a commercial route with historical importance.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref>] In prevalence studies, the highest rate was reported in Turkey, with 421 cases for every 100,000 people.[<xref rid="R5" ref-type="bibr">5</xref>]</p><p>Although the rates of ocular involvement associated with BD are approximately 30%&#x02013;70%, most BD patients (63%&#x02013;100%) have bilateral inflammation.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R6" ref-type="bibr">6</xref>] While unilateral and isolated anterior segment involvement is rare in Beh&#x000e7;et&#x02019;s associated uveitis (BAU), it typically presents as bilateral nongranulomatous panuveitis or retinal vasculitis.[<xref rid="R2" ref-type="bibr">2</xref>] Posterior segment complications, such as macular degeneration and scarring, optic atrophy, retinal atrophy, or tractional retinal detachment, which may develop after recurrent uveitis attacks, are the most important causes of irreversible vision loss associated with BAU.[<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref>] Suppression of inflammation and maintenance of remission with appropriate treatment methods are very important for visual prognosis.</p><p>With the introduction of biological agents, inflammation control has been observed to be better in cases resistant to conventional treatment. In this context, the safety and efficacy of adalimumab (ADA; Humira &#x000ae;, Abbvie Inc., North Chicago, Illinois, USA) and infliximab (IFX; Remicade &#x000ae;, Janssen Biotech Inc., Horsham, Pennsylvania, USA) treatments in cases of noninfectious uveitis have been reported in various studies.[<xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref><xref rid="R12" ref-type="bibr">12</xref>] While IFX is still used off-label in the treatment of BAU in countries other than Japan, ADA has received FDA and EMA approval for the treatment of noninfectious intermediate, posterior, and panuveitis thanks to multicenter phase 3 studies, VISUAL-I-II-III.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref>]</p><p>In cases of Beh&#x000e7;et&#x02019;s uveitis, the use of imaging methods is very important for detecting the diagnostic features of the disease, disease activity, response to treatment, and structural changes that develop due to the disease. Optical coherence tomography (OCT) allows the noninvasive examination of posterior segment lesions, with cystoid macular edema being the most common in BAU cases. Quantitative macular thickness measurements can be made in the follow-up of BAU patients receiving anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment.[<xref rid="R16" ref-type="bibr">16</xref>] It is possible to evaluate the choroid histologically and cross-sectionally using the enhanced depth imaging (EDI-OCT) mode of existing OCT devices. Ishikawa <italic toggle="yes">et al</italic>.[<xref rid="R17" ref-type="bibr">17</xref>] have shown that subfoveal choroidal thickness (SFCT) increases during an attack of Beh&#x000e7;et&#x02019;s uveitis.</p><p>In this study, we aimed to retrospectively analyze and share the demographic characteristics, clinical course of ocular findings, development of complications, final visual prognoses, and final OCT findings of patients who were diagnosed with BAU. These patients were divided into three groups: those treated with IFX, those treated with ADA, and those who switched protocols between these two treatment modalities. To the best of our knowledge, this is the first three-way comparison of BAU patients in Turkey who underwent treatment with only ADA, who were treated with only IFX, and who were treated with both protocols.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><sec id="sec2-1"><title>Study population</title><p>The charts of adult (18 years of age or older) patients with uveitis related to Beh&#x000e7;et&#x02019;s disease who applied to a single referral center between January 2014 and September 2020 and were treated with anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents and followed up at least one year after the initiation of the biologic agent were retrospectively reviewed. Approval from the Institutional Ethics Board was obtained before the study was conducted. and study-related procedures were performed after patient consent was obtained. The study followed the tenets of the Declaration of Helsinki, and diagnosis of Beh&#x000e7;et&#x02019;s disease was made according to the criteria established by the International Study Group for Beh&#x000e7;et&#x02019;s Disease.[<xref rid="R18" ref-type="bibr">18</xref>] Patients who were undergoing anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment initiated at other institutions were excluded from the study. Pediatric cases were not included in the study due to the insufficient number of cases followed by BAU.</p></sec><sec id="sec2-2"><title>Data gathering</title><p>The chart review of patients who were diagnosed with Beh&#x000e7;et&#x02019;s disease-related panuveitis and needed to be given anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents for various reasons was conducted in May and June of 2021. Anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment was initiated in this cohort for the following reasons: uncontrolled ocular inflammation with previous medication (primary failure), development of adverse events due to systemic therapy, absence of the ongoing treatment agent from the market, macula involvement, and presence of occlusive retinal vasculitis at presentation. Additionally, the following data were acquired for each participant: age, gender, previous systemic treatment, latent tuberculosis status, remission status prior to anti-TNF-<italic toggle="yes">&#x003b1;</italic> initiation, circumstances that warranted anti-TNF-<italic toggle="yes">&#x003b1;</italic> administration, date of first administration of the anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent and its type (IFX or ADA), best-corrected visual acuity (in logMAR), and central macular thickness (in &#x000b5;m) at the first anti-TNF-<italic toggle="yes">&#x003b1;</italic> injection and at the last follow-up visit; also acquired were the anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment protocol, dosage, injection interval and adjunctive drugs used with the anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent, the systemic steroid dosage at the first anti-TNF-<italic toggle="yes">&#x003b1;</italic> administration visit and the last follow-up visit, the duration of the anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment, the existence of a switch between the two anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents during the follow-up and the reason for the switch, the remission state at the last follow-up visit, the presence of a recurrence of the ocular inflammation during the anti-TNF-<italic toggle="yes">&#x003b1;</italic> therapy, the total duration of anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment, the best corrected visual acuity (BCVA) and central macular thickness at the last visit, and any adverse events related to the anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents.</p></sec><sec id="sec2-3"><title>Anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment and switching protocol</title><p>An in-depth physical and laboratory evaluation was conducted on each patient before the initiation of anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment. It comprised a complete blood test for transaminases and C-reactive protein (CRP), hepatitis B, hepatitis C, VZV immunoglobulin M/G, syphilis and HIV serology, <italic toggle="yes">in-vitro</italic> QuantiFERON-TB-Gold&#x000ae; test, tuberculin protein purified derivative (PPD) skin testing, a chest radiograph, and a check that immunization certificates were up to date. All patients were consulted by the neurology department in terms of the presence or suspicion of demyelinating disease before anti-TNF agents were initiated. The drug safety monitoring form was filled in and signed by an ophthalmologist, an infectious disease specialist, and an internal medicine specialist at the initiation of the anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment and at 3-month intervals during the follow-ups. Latent tuberculosis prophylaxis (isoniazid 100 mg) was initiated 1 month prior to the initiation of the biological agent and continued for at least 9 months.</p><p>The IFX dosage was 5 mg/kg and administered via slow intravenous infusion, with an antihistaminic premedication at 0, 2, and 6 weeks and every 4 weeks thereafter. ADA treatment was administered subcutaneously at an initial dose of 80 mg, followed by 40 mg every other week, starting one week after the initial dose.</p><p>A switch between the two anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents was warranted in some cases. Among the reasons given were the loss of effectiveness over time of the first anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent (secondary failure), the development of drug-related adverse events, and the patient&#x02019;s low compliance with drug use. In particular, if there were no adverse events to ADA, the ADA injection intervals were adjusted to 1-week intervals after approval was obtained from the Health Ministry, in case remission failed to be achieved before the switch was made to IFX infusions. The switching protocol was as follows: The IFX infusion was administered after 2 weeks had passed from the last ADA injection date, and the ADA was administered after 1 month had passed from the previous IFX infusion date. The patients were classified according to the treatment regime that they had gone through as the IFX group, the ADA group, and the switched group.</p><p>To exclude hepatotoxicity and other infectious processes, a complete blood count, CRP, and transaminase levels were scanned every month in patients who received IFX and every 2 months in patients who received ADA. During treatment, symptoms such as cough, sputum, and weight loss were questioned in terms of TB reactivity, and patients with suspicions were referred to departments such as chest diseases and infectious diseases.</p></sec><sec id="sec2-4"><title>Treatment outcome measures</title><p>The primary outcome measure was a steroid-free (&#x02264;5 mg/day) remission state (defined as quiescence or at least a two-step decrease in the level of inflammation based on the anterior chamber cell score or vitreous haze score) of the patient at the last visit. Any exacerbation of the uveitis (defined as a &#x02265;2+ increment or an increase from 3 to 4 in anterior chamber cell grade, with an increase in vitreous haze score, decrease in BCVA, or the development of cystoid macular edema (CME) was defined as relapse, and the remission state was defined as the lack of any relapses after at least 3 months of follow-up according to the standardization of uveitis nomenclature working group criteria.[<xref rid="R19" ref-type="bibr">19</xref>] Fundus fluorescent angiography (FFA) was routinely performed in all patients to determine the presence of angiographic leakage before and after treatment. The FFA was evaluated for macular edema, retinal vasculitis, retinitis, choroiditis, and papillitis. Retinal vasculitis was defined as the appearance of angiographic leakage, staining, or occlusion in the FFA. Choroiditis and retinitis focus were classified as active or inactive according to either their appearance on fundus examination or the staining status of the lesion in the FFA [<xref rid="IJO.IJO_2011_23-F1" ref-type="fig">Fig. 1</xref>].</p><fig position="float" id="IJO.IJO_2011_23-F1"><label>Figure 1</label><caption><p>Evaluation of patients with FFA prior to anti-TNF-<italic toggle="yes">&#x003b1;</italic> therapy (a) macular edema-related leakage in the right eye, (b) optic disc head staining and macular edema-related leak area in the same patient&#x02019;s left eye, (c) optic disc head and along the vascular network inflammatory leak areas in the right eye (d) mild macular leak area in the left eye of the same patient, (e) retinitis focus in the right eye fundus photograph of a different patient (f) inflammatory leak in the area compatible with the retinitis focus</p></caption><graphic xlink:href="IJO-72-521-g001" position="float"/></fig><p>The secondary outcome objectives were determined to be an increase in BCVA, the resolution of macular edema, and a reduced dosage of systemic corticosteroids. BCVA was assessed using the Snellen chart and converted to logMAR equivalents. An increase of more than 0.2 logMAR in BCVA at the last visit compared to the level at the initiation of the anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent was defined as &#x0201c;improved BCVA.&#x0201d; In contrast, a deterioration of more than 0.2 logMAR was described as &#x0201c;worsened BCVA.&#x0201d; Alterations in BCVA between these two cutoff points were defined as &#x0201c;no change in BCVA.&#x0201d; The presence of macular edema was defined as a central macular thickness &#x0003e;300 &#x000b5;m. &#x0201c;Improved macular edema&#x0201d; was defined as the disappearance of macular edema at the last visit compared to the state at treatment initiation or at least a 20% reduction in central macular thickness measured by optical coherence tomography (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany). In addition, SFCT was measured by EDI-OCT (Heidelberg Engineering, Heidelberg, Germany) at all visits. SFCT was defined as the vertical distance at the fovea between the hyperreflective line corresponding to the retinal pigment epithelium and the chorioscleral interface.</p></sec><sec id="sec2-5"><title>Statistical analysis</title><p>SPSS software version 22 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. The distribution of the variables was analyzed using the Kolmogorov&#x02013;Smirnov/Shapiro&#x02013;Wilk test. The continuous variables were denoted as mean &#x000b1; standard deviation, while the categorical data were expressed as absolute numbers and percentages. The initial visit and last visit variables were compared using a paired-sample <italic toggle="yes">t</italic>-test or a Wilcoxon signed-rank test. A Chi-square test was used in the comparative analysis of the categorical variables. The Kruskal&#x02013;Wallis test was used to compare the primary and secondary outcome measures between the treatment regime groups. The statistical significance rate was set at <italic toggle="yes">P</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>The patients&#x02019; demographic and clinical characteristics are summarized in <xref rid="IJO.IJO_2011_23-T1" ref-type="table">Table 1</xref>. Sixty-three eyes of 33 patients were included in the study; 21 (63.6%) of the 33 patients were male. The mean age of the patients was 30.36 years. There was bilateral involvement in 30 patients (90.9%) and unilateral involvement in 3 patients (9.1%) at the time of admission.</p><table-wrap position="float" id="IJO.IJO_2011_23-T1"><label>Table 1</label><caption><p>The Demographic and clinical features of patients with Beh&#x000e7;et uveitis along with previous and ongoing systemic treatments are summarized</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Patient no.</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Age (years)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Gender (M/F)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Laterality (R/L)</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Previous DMARDs treatment</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Reason of anti-TNF-<italic toggle="yes">&#x003b1;</italic> initiation</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Initiated anti-TNF-<italic toggle="yes">&#x003b1;</italic></th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Switch existence (+/-)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Switch reason</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Total anti-TNF-<italic toggle="yes">&#x003b1;</italic> duration (months)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OV</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MR</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA&#x02192;IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">LC</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">LC</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MR</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">LC</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OV</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA&#x02192;IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA&#x02192;IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">SF</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MR</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFN-<italic toggle="yes">&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AE</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">LC</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">R&#x00026;L</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AZA + CSA</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Failure</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">LC</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>M: Male, F: Female, R: Right, L: Left, &#x00026;: And, DMARDs: Disease-modifying antirheumatic drugs, TNF- &#x003b1;: Tumor necrosis factor-alpha, IFN-&#x003b1;: Interferon-alpha, AZA: Azathioprine, CSA: Cyclosporin-A, ADA: Adalimumab, IFX: Infliximab, AE: Adverse events, OV: Occlusive vasculitis, Macular Retinitis: MR, LAD: Lack of access to the drug, SF: secondary failure LC: Low compliance, &#x02192;: Switched to</p></fn></table-wrap-foot></table-wrap><p>All patients who presented with acute inflammatory attacks, excluding infectious pathologies, were treated with rapid-acting systemic anti-inflammatory corticosteroids after a detailed systemic investigation. When the corticosteroid dose was reduced, other steroid-sparing agents were added for the long-term control of inflammation. While IFN-<italic toggle="yes">&#x003b1;</italic> was given to 19 of the patients and 9 of the patients were treated with AZA plus CSA, direct anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment was preferred due to the detection of occlusive vasculitis and macular retinitis in 5 patients at the time of admission [<xref rid="IJO.IJO_2011_23-T1" ref-type="table">Table 1</xref>]. Anti-TNF-<italic toggle="yes">&#x003b1;</italic> therapy was started in all 9 patients who received AZA plus CSA combination therapy because of insufficient control of inflammation (primary failure). The reasons for switching to anti-TNF-<italic toggle="yes">&#x003b1;</italic> therapy in 19 patients using IFN-<italic toggle="yes">&#x003b1;</italic> were as follows: primary failure (insufficient inflammation control) in six patients (31.6%), difficulty in accessing the drug in three patients (15.8%), and development of adverse events in ten patients (52.6%). Before treatment, latent TB was detected in five patients (15.1%), and INH prophylaxis was applied. Adverse events were major depression in six patients (31.6%), hair loss in three patients (15.8%), and bicytopenia in one patient [5.2%; <xref rid="IJO.IJO_2011_23-T3" ref-type="table">Table 3</xref>].</p><table-wrap position="float" id="IJO.IJO_2011_23-T2"><label>Table 2</label><caption><p>Comparison analysis of BCVA, CMT, SFCT measurements, and systemic corticosteroid dosage between pre-treatment and last visit periods</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Pre-anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Last visit</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> (<italic toggle="yes">Z</italic>-Score)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BCVA (logMAR)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean&#x000b1;SD<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,65&#x000b1;0,86<break/>0&#x02013;3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,34&#x000b1;0,59<break/>0&#x02013;3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0,001* (&#x02212;4,715)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic corticosteroid dosage (mg/day)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean&#x000b1;SD<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20,94&#x000b1;17<break/>0&#x02013;48</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,42&#x000b1;1,37<break/>0&#x02013;5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0,001* (<italic toggle="yes">Z</italic>=&#x02212;4,130)</td></tr><tr><td align="left" rowspan="1" colspan="1">CMT (&#x003bc;m)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean&#x000b1;SD<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">308&#x000b1;97,1<break/>154&#x02013;703</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">267,4&#x000b1;44,6<break/>139&#x02013;385</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0,001* (&#x02212;5,192)</td></tr><tr><td align="left" rowspan="1" colspan="1">SFCT (&#x003bc;m)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean&#x000b1;SD<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">355,4&#x000b1;95<break/>116&#x02013;654</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">307,3&#x000b1;84,6<break/>82&#x02013;482</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0,001* (&#x02212;3,683)</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>BCVA: Best-corrected visual acuity, CMT: Central macular thickness, SFCT: Subfoveal choroidal thickness, SD: Standard deviation, TNF &#x003b1;: Tumor necrosis factor alpha, &#x003bc;m: Micrometer, mg: Milligram, logMAR: Logarithm of minimum angle of resolution. *Wilcoxon Signed Ranks Test</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="IJO.IJO_2011_23-T3"><label>Table 3</label><caption><p>Previous and ongoing treatment regimens and adverse events were seen during their usage. Anti-TNF &#x003b1; related adverse events and switch reasons and the pre-treatment and last visit remission states were also summarized</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Anti-TNF-&#x003b1; agent</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e; IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9 (27,3)</td></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e; ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16 (48,5)</td></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e; IFX&#x02192;ADA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (15,1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Low compliance (<italic toggle="yes">n</italic>=4)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Adverse event (<italic toggle="yes">n</italic>=1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e; ADA&#x02192;IFX</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (9,1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Low compliance (n=1)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Adverse event (n=1)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Secondary failure (<italic toggle="yes">n</italic>=1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adjunctive agent</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; None<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; AZA<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; AZA + oral corticosteroid</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9 (27,3)<break/>21 (63,6)<break/>3 (9,1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Latent TBC presence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; None<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; INH prophylaxis given</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">28 (84,9)<break/>5 (15,1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events or problems related to the previous treatment</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e;AZA + CSA (<italic toggle="yes">n</italic>=9)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Primary failure</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">=&#x0003e;IFN-<italic toggle="yes">&#x003b1;</italic> (<italic toggle="yes">n</italic>=19)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Bicytopenia<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Hair loss<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Major depression<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Lack of access to the drug<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Primary failure</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (5,2)<break/>3 (15,8)<break/>6 (31,6)<break/>3 (15,8)<break/>6 (31,6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events related to anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Allergic reaction (IFX)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Hypotension (ADA)<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Zona Zoster (IFX)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (3)<break/>1 (3)<break/>1 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Remission state at the anti-TNF-<italic toggle="yes">&#x003b1;</italic> initiation time</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Active<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; In remission</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">21 (63,6)<break/>12 (36,4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Remission state at the last visit</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Active<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; In remission</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (15,1)<break/>28 (84,9)</td></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>TNF- &#x003b1;: Tumor necrosis factor-alpha, IFN-&#x003b1;: Interferon-alpha, AZA: Azathioprine, CSA: Cyclosporin-A, ADA: Adalimumab, IFX: Infliximab, SD: Standard deviation, n: Number, %: Percentage</p></fn></table-wrap-foot></table-wrap><p>The mean follow-up period of the patients was 16.60 months, during which 9 (27.3%) were using IFX, 16 (48.5%) were using ADA, and 8 (5 IFX to ADA, 3 ADA to IFX) switched protocol. The main reasons for the decision to switch were patients&#x02019; low compliance with drug administration and the occurrence of drug-related side effects. However, one patient switched to IFX due to the development of resistance to ADA treatment over time [secondary failure; <xref rid="IJO.IJO_2011_23-T1" ref-type="table">Tables 1</xref>-<xref rid="IJO.IJO_2011_23-T3" ref-type="table">3</xref>]. During the anti-TNF<italic toggle="yes">-&#x003b1;</italic> treatment, 21 (63.6%) of the patients required AZA, and 3 (9.1%) required AZA plus oral corticosteroid combinations. Anti-TNF-<italic toggle="yes">&#x003b1;</italic> was administered as a single agent in nine (27.3%) patients. An allergic reaction developed in one (3%) patient, and shingles developed in one (3%) patient who received IFX treatment. Hypotension developed in one (3%) patient who received ADA; this was considered a drug-related side effect [<xref rid="IJO.IJO_2011_23-T3" ref-type="table">Table 3</xref>]. When detailed ophthalmological examinations, including anterior chamber cell and vitreal haze status, BCVA change, CME development, and FFA findings were evaluated together, 21 (63.6%) patients had active inflammation findings before anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment, but this value decreased to five (15.1%) patients at the last visit after treatment [<xref rid="IJO.IJO_2011_23-T3" ref-type="table">Table 3</xref>].</p><p>Mean BCVA values were statistically significantly increased at the last visit compared to the situation before anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment (0.65 &#x000b1; 0.86 logMAR vs. 0.34 &#x000b1; 0.59 logMAR, <italic toggle="yes">P</italic> &#x0003c; 0.001). CMT (308 &#x000b1; 97.1 vs. 267.4 &#x000b1; 44.6, <italic toggle="yes">P</italic> &#x0003c; 0.001) and SFCT (355.4 &#x000b1; 95 vs. 307.3 &#x000b1; 84.6, <italic toggle="yes">P</italic> &#x0003c; 0.001) values decreased significantly after treatment. At the last visit, the need for systemic corticosteroid therapy was considerably reduced compared to the initial dose. While the initial corticosteroid dose was 20.94 &#x000b1; 17 mg/day (0&#x02013;48 mg/day) on average, it was 0.42 &#x000b1; 1.37 mg/day (0&#x02013;5 mg/day) at the last visit [<italic toggle="yes">P</italic> &#x0003c; 0.001; <xref rid="IJO.IJO_2011_23-T2" ref-type="table">Table 2</xref>]. At the last visit, 30 of the 33 patients (90.9%) were not using oral steroids.</p><p>The cases were divided into two groups&#x02014;switched (8 patients) and nonswitched (25) patients&#x02014;and BCVA, CMT, and SFCT changes between the first visit and the last visit were compared. According to this analysis, the BCVA change in the BAU patients in the switched group was statistically significantly increased compared to the nonswitched group (<italic toggle="yes">P</italic> = 0.038). There was no significant difference between the switch group and the nonswitch group in terms of CMT and SFCT changes (<italic toggle="yes">P</italic> = 0.817 and <italic toggle="yes">P</italic> = 0.850, respectively).</p><p>When the patients who were treated with anti-TNF-<italic toggle="yes">&#x003b1;</italic> were divided into IFX, ADA, and switched groups, the mean age of the groups was similar (<italic toggle="yes">P</italic> = 0.98). Improved BCVA was observed at the last visit compared to pretreatment status in all groups. There was a statistically significant increase in the switched group compared to the others (<italic toggle="yes">P</italic> = 0.05; BCVA change: IFX = 0.23 logMAR, ADA = 0.29 logMAR, switched = 0.46 logMAR). At the last visit, the mean CMT values of all groups had decreased and were &#x0003c;300 &#x000b5;m. Although the reduction rate was higher in the IFX group than in the others, the decrease in mean CMT values was not &#x0003e;20% in any group (CMT change rates: IFX = 14.42%, ADA = 9.62%, switched = 7.58%). SFCT values decreased in all three groups at the last visit compared to pretreatment. There was no significant difference between the groups in terms of reduction rates (<italic toggle="yes">P</italic> = 0.98; SFCT change: IFX = 38.89 &#x000b5;m, ADA = 50.81 &#x000b5;m, switched = 39.25 &#x000b5;m). The mean follow-up period was over 1 year in all three groups. The group with the longest follow-up period was IFX at 19.78 months, while the shortest follow-up period was the ADA group at 13.75 months [<xref rid="IJO.IJO_2011_23-T4" ref-type="table">Table 4</xref>].</p><table-wrap position="float" id="IJO.IJO_2011_23-T4"><label>Table 4</label><caption><p>Comparison analysis between three treatment groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="7" rowspan="1">Anti-TNF-<italic toggle="yes">&#x003b1;</italic> Treatment Modality<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">IFX (<italic toggle="yes">n</italic>=9)<break/>Mean</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">ADA (<italic toggle="yes">n</italic>=16)<break/>Mean</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Switched (<italic toggle="yes">n</italic>=8)<break/>Mean</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
<sup>x</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">29,22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30,19</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32,00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,98</td></tr><tr><td align="left" rowspan="1" colspan="1">BCVA pre-treatment (logMAR)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,37</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,49</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,91</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,28</td></tr><tr><td align="left" rowspan="1" colspan="1">BCVA last visit (logMAR)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,13</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,21</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,32</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,65</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in BCVA (logMAR)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;0,23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;0,29</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;0,46</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,055</td></tr><tr><td align="left" rowspan="1" colspan="1">CMT pre-treatment (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">316,67</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">307,25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">280,00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,84</td></tr><tr><td align="left" rowspan="1" colspan="1">CMT last visit (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">271,00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">277,69</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">258,75</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,75</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in CMT (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;45,67</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;29,56</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;21,25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,82</td></tr><tr><td align="left" rowspan="1" colspan="1">SFCT pre-treatment (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">367,11</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">339,88</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">356,50</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,61</td></tr><tr><td align="left" rowspan="1" colspan="1">SFCT last visit (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">328,22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">289,06</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">317,25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,60</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in SFCT (&#x003bc;m)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;38,89</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;50,81</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;39,25</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,98</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment duration (months)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">19,78</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">13,75</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18,75</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0,02</td></tr></tbody></table><table-wrap-foot><fn id="TF-F4"><p>Anti-TNF &#x003b1;: anti-tumor necrosis factor alpha, BCVA: Best corrected visual acuity, logMAR: logaritm of minimal angle of resolution, CMT: central macular thickness, &#x003bc;m: micrometer, SFCT: sub-foveal choroidal thickness. <sup>x</sup>Kruskal-Wallis test</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>The European League Against Rheumatism (EULAR) has recently made up-to-date recommendations regarding the treatment algorithm for BAU patients. Some of these recommendations are as follows: any patient with posterior segment involvement should be treated with AZA, CSA, IFN-<italic toggle="yes">&#x003b1;</italic>, or anti-TNF-<italic toggle="yes">&#x003b1;</italic>. During initial or recurrent acute episodes of vision-threatening BAU, patients should be initiated on high-dose glucocorticoids, IFN-<italic toggle="yes">&#x003b1;</italic>, or IFX.[<xref rid="R20" ref-type="bibr">20</xref>] Shortly after the preparation of these recommendations, the efficacy of ADA in the treatment of noninfectious intermediate, posterior, and panuveitis cases was proven in VISUAL-I-II-III, which were randomized controlled clinical studies.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref>]</p><p>Various studies in the literature have evaluated the role of ADA and IFX treatment in resistant BAU cases.[<xref rid="R12" ref-type="bibr">12</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref>] Takeuchi <italic toggle="yes">et al</italic>.[<xref rid="R21" ref-type="bibr">21</xref>] demonstrated in their multicenter retrospective study that IFX treatment provided 90% remission and reduced infusion frequency. In another study, patients resistant to corticosteroid, AZA, and CSA combination therapy were switched to IFX infusion therapy, and a significant decrease in the average number of attacks and the need for corticosteroid use was observed.[<xref rid="R22" ref-type="bibr">22</xref>] Additionally, IFX drug retention rates in BAU patients were as high as 89.03% at the end of the first year and 47.11% at the end of the tenth year. It has been observed that the simultaneous use of disease-modifying antirheumatic drug (DMARD) therapy is not superior to IFX monotherapy in these patients.[<xref rid="R24" ref-type="bibr">24</xref>] FFA scores improved when ADA was added to conventional treatment in BAU patients with refractory retinal vasculitis.[<xref rid="R25" ref-type="bibr">25</xref>] ADA drug retention rates in BAU cases were determined to be 63.5% at the end of the second year, and the use of DMARDs had no effect on these rates.[<xref rid="R26" ref-type="bibr">26</xref>]</p><p>Few randomized controlled studies have compared IFX and ADA treatments in resistant BAU cases, and both treatment protocols are reported to be safe and effective in this regard.[<xref rid="R11" ref-type="bibr">11</xref><xref rid="R16" ref-type="bibr">16</xref><xref rid="R27" ref-type="bibr">27</xref><xref rid="R28" ref-type="bibr">28</xref>] In addition, some studies suggest that ADA treatment is more effective,[<xref rid="R27" ref-type="bibr">27</xref>] and others show that IFX treatment reduces recurrence rates in vision-threatening noninfectious uveitis cases.[<xref rid="R29" ref-type="bibr">29</xref>] The success criteria in these studies were determined according to parameters such as intraocular inflammation remission, CMT, BCVA, and systemic glucocorticoid requirement. According to our literature review, almost all of the reported patients who underwent the switched protocol between anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents in BAU patients were switched from IFX to ADA therapy due to loss of efficacy.[<xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref>] These studies were at the case report level and limited patient data were available. Olivieri <italic toggle="yes">et al</italic>.[<xref rid="R33" ref-type="bibr">33</xref>] studied 17 BAU patients who underwent the switched protocol; due to the loss of IFX efficacy and the development of infusion reaction in these patients, ADA treatment was started, remission was observed in 52.94% of patients, and unresponsiveness to treatment in 29.41% of patients during follow-up.</p><p>In our study, IFX and ADA treatments were applied together or alone with adjunctive immunosuppressive agents in resistant BAU cases. In addition, eight patients needed a switch between these two anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents for various reasons. The reason for passing from IFX to ADA was low compliance in drug administration in four patients and the development of an allergic reaction in one patient. Reasons for switching from ADA to IFX were adverse events (development of hypotension), low compliance in drug administration, and development of drug resistance over time. While the remission rate was 36.4% (12 patients) before anti-TNF-<italic toggle="yes">&#x003b1;</italic> treatment, it increased to 84.9% (28 patients) at the last visit after treatment. The mean BCVA values of all participants before the use of anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents increased significantly at the last posttreatment visit. Although improved BCVA levels were achieved in all three groups, the BCVA increase in the switched group seemed to be higher compared to the others. This result may enable us to have more courage when making the decision to change biological agents when needed in the follow-up of BAU patients. Additionally, mean CMT values decreased significantly at the last visit compared to the first visit in the entire study population. Although the CMT change was more pronounced in the IFX group, there was no significant difference in change between the three groups. Systemic corticosteroid requirement was significantly reduced at the last follow-up compared to before treatment. Only three (9.1%) patients continued to need systemic corticosteroids at the last visit.</p><p>Recent studies have reported enlargement of choroidal vascular structures associated with active inflammation and increased subfoveal choroidal thickness, which can be measured by EDI-OCT, in BAU patients.[<xref rid="R34" ref-type="bibr">34</xref><xref rid="R35" ref-type="bibr">35</xref><xref rid="R36" ref-type="bibr">36</xref>] Shirahama <italic toggle="yes">et al</italic>.[<xref rid="R34" ref-type="bibr">34</xref>] applied EDI-OCT and FFA during the active and remission phases of Beh&#x000e7;et&#x02019;s uveitis patients and observed that SFCT increased in the macular region in the active phase in correlation with FFA leak scores. Another study found a correlation between the decrease in choroidal thickening and the improvement in FFA findings.[<xref rid="R37" ref-type="bibr">37</xref>] Choroidal thickness has been shown to decrease over time in Beh&#x000e7;et&#x02019;s patients in relation to disease duration and inflammatory attacks; however, although EDI-OCT data taken only during remission periods were examined in this study, anterior chamber reaction and vitreal haze were evaluated as inflammation markers, and possible activation with FFA was not excluded.[<xref rid="R38" ref-type="bibr">38</xref>] Another study reported that SFCT decreased in five patients receiving anti-TNF-<italic toggle="yes">&#x003b1;</italic> (IFX) therapy, and this decrease correlated with anterior and posterior segment inflammation scores.[<xref rid="R39" ref-type="bibr">39</xref>] In our study, we observed that SFCT values decreased in correlation with BCVA and CMT. Based on this result, we think that SFCT values may be related to the active inflammation control of IFX and ADA treatment and that SFCT measurements may be useful as a noninvasive method in treatment follow-up. However, when the switched group was compared with the nonswitched groups, no superiority of CMT and SFCT was observed. For this reason, evaluating CMT and SFCT data together in the follow-up of BAU patients may be a more appropriate approach.</p><p>IFX treatment is administered as an intravenous infusion with a one-day hospitalization at intervals of 8 weeks or less. Since BAU patients need long-term treatment, transportation difficulties, and increased costs limit the sustainability of the treatment. ADA is another anti-TNF-<italic toggle="yes">&#x003b1;</italic> agent that has been approved for the treatment of noninfectious uveitis and can be administered subcutaneously. Serum antidrug antibodies may develop against anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents, leading to immunogenicity. In the presence of these antibodies, serum anti-TNF-<italic toggle="yes">&#x003b1;</italic> concentrations decrease, resulting in a shorter duration of treatment response.[<xref rid="R40" ref-type="bibr">40</xref>] IFX has higher immunogenicity due to its mouse-based content, so the risk of developing antidrug antibodies after long-term use is higher. In this case, since combined use with antimetabolite drugs will be beneficial, IFX use requires combined antimetabolite drugs. However, the risk of ADA immunogenicity is lower, and it is safer to use as monotherapy.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R41" ref-type="bibr">41</xref>] Adverse reactions have been reported to occur in an average of 2.62% of patients during anti-TNF-<italic toggle="yes">&#x003b1;</italic> therapy. These are local reactions such as gastroenteritis, hypotension, infusion reaction, pneumonia, miliary TB, and lymphoma.[<xref rid="R10" ref-type="bibr">10</xref>] In our case series, side effects such as hypotension, shingles, and allergic reactions occurred in three (9.1%) patients, and follow-up was continued by switching between medications.</p><p>Our study has some limitations, such as being retrospective, having a relatively small number of patients, and having different follow-up times between subgroups. Due to the different and insufficient number of samples, we did not have the chance to compare the cases whose treatment required combination with anti-TNF-<italic toggle="yes">&#x003b1;</italic> monotherapy with those that did not. In this regard, it may be useful to conduct prospective studies with a larger number of participants.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>In this study, which included only BAU cases, the data of IFX, ADA, and switched groups were evaluated. In BAU cases unresponsive to conventional treatments, anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents used as monotherapy or in combination were similarly effective and safe in terms of reducing the need for systemic corticosteroid use, suppressing intraocular inflammation, providing remission, and protecting vision levels in the long term. In addition, switching between two anti-TNF-<italic toggle="yes">&#x003b1;</italic> agents may contribute to overall improvement in final visual acuity.</p><sec sec-type="funding-statement" id="sec2-6"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-7"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beh&#x000e7;et</surname><given-names>HJDW</given-names></name></person-group><article-title>Uber rezidivierende Aphthose, duruch ein Virus verursachte Geschwre am Mund am Auge und an den Genitalien</article-title><source>Derm Wochr</source><year>1937</year><volume>105</volume><fpage>1151</fpage></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;akar &#x000d6;zdal</surname><given-names>P</given-names></name></person-group><article-title>Beh&#x000e7;et&#x02019;s uveitis: Current diagnostic and therapeutic approach</article-title><source>Turk J Ophthalmol</source><year>2020</year><volume>50</volume><fpage>169</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">32631005</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khairallah</surname><given-names>M</given-names></name>
<name><surname>Accorinti</surname><given-names>M</given-names></name>
<name><surname>Muccioli</surname><given-names>C</given-names></name>
<name><surname>Kahloun</surname><given-names>R</given-names></name>
<name><surname>Kempen</surname><given-names>JH</given-names></name></person-group><article-title>Epidemiology of Beh&#x000e7;et disease</article-title><source>Ocular Immunol Inflamm</source><year>2012</year><volume>20</volume><fpage>324</fpage><lpage>35</lpage></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>SB</given-names></name>
<name><surname>Cho</surname><given-names>S</given-names></name>
<name><surname>Bang</surname><given-names>D</given-names></name></person-group><article-title>New insights in the clinical understanding of Beh&#x000e7;et&#x02019;s disease</article-title><source>Yonsei Med J</source><year>2012</year><volume>53</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22187230</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azizlerli</surname><given-names>G</given-names></name>
<name><surname>K&#x000f6;se</surname><given-names>AA</given-names></name>
<name><surname>Sarica</surname><given-names>R</given-names></name>
<name><surname>G&#x000fc;l</surname><given-names>A</given-names></name>
<name><surname>Tutkun</surname><given-names>IT</given-names></name>
<name><surname>Kula&#x000e7;</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Prevalence of Beh&#x000e7;et&#x02019;s disease in Istanbul, Turkey</article-title><source>Int J Dermatol</source><year>2003</year><volume>42</volume><fpage>803</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14521694</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greco</surname><given-names>A</given-names></name>
<name><surname>De Virgilio</surname><given-names>A</given-names></name>
<name><surname>Ralli</surname><given-names>M</given-names></name>
<name><surname>Ciofalo</surname><given-names>A</given-names></name>
<name><surname>Mancini</surname><given-names>P</given-names></name>
<name><surname>Attanasio</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Beh&#x000e7;et&#x02019;s disease: New insights into pathophysiology, clinical features and treatment options</article-title><source>Autoimmun Rev</source><year>2018</year><volume>17</volume><fpage>567</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">29631062</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozdal</surname><given-names>PC</given-names></name>
<name><surname>Orta&#x000e7;</surname><given-names>S</given-names></name>
<name><surname>Ta&#x0015f;kintuna</surname><given-names>I</given-names></name>
<name><surname>Firat</surname><given-names>E</given-names></name></person-group><article-title>Posterior segment involvement in ocular Beh&#x000e7;et&#x02019;s disease</article-title><source>Eur J Ophthalmol</source><year>2002</year><volume>12</volume><fpage>424</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12474927</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tugal-Tutkun</surname><given-names>I</given-names></name>
<name><surname>Onal</surname><given-names>S</given-names></name>
<name><surname>Altan-Yaycioglu</surname><given-names>R</given-names></name>
<name><surname>Huseyin Altunbas</surname><given-names>H</given-names></name>
<name><surname>Urgancioglu</surname><given-names>M</given-names></name></person-group><article-title>Uveitis in Beh&#x000e7;et disease: An analysis of 880 patients</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>138</volume><fpage>373</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15364218</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fabiani</surname><given-names>C</given-names></name>
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Rigante</surname><given-names>D</given-names></name>
<name><surname>Emmi</surname><given-names>G</given-names></name>
<name><surname>Lopalco</surname><given-names>G</given-names></name>
<name><surname>Sota</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Efficacy of anti-tumour necrosis factor-&#x003b1; monoclonal antibodies in patients with non-infectious anterior uveitis</article-title><source>Clin Exp Rheumatol</source><year>2019</year><volume>37</volume><fpage>301</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">30719968</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>Z</given-names></name>
<name><surname>Yang</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Su</surname><given-names>W</given-names></name>
<name><surname>Liang</surname><given-names>D</given-names></name></person-group><article-title>Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets&#x02019; disease-associated uveitis: A systematic review and meta-analysis</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>941</fpage><comment>doi: 10.3389/fphar. 2020.00941</comment><pub-id pub-id-type="pmid">32670062</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tosi</surname><given-names>GM</given-names></name>
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Rigante</surname><given-names>D</given-names></name>
<name><surname>Sota</surname><given-names>J</given-names></name>
<name><surname>Emmi</surname><given-names>G</given-names></name>
<name><surname>Lopalco</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Efficacy of monoclonal anti-tumour necrosis factor-&#x003b1; antibodies in uveitic macular oedema</article-title><source>Clin Exp Rheumatol</source><year>2020</year><volume>38</volume><fpage>621</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">31694738</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohno</surname><given-names>S</given-names></name>
<name><surname>Umebayashi</surname><given-names>I</given-names></name>
<name><surname>Matsukawa</surname><given-names>M</given-names></name>
<name><surname>Goto</surname><given-names>T</given-names></name>
<name><surname>Yano</surname><given-names>T</given-names></name></person-group><article-title>Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh&#x000e7;et&#x02019;s disease: A large-scale, long-term postmarketing surveillance in Japan</article-title><source>Arthritis Res Ther</source><year>2019</year><volume>21</volume><fpage>2</fpage><pub-id pub-id-type="pmid">30611312</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaffe</surname><given-names>GJ</given-names></name>
<name><surname>Dick</surname><given-names>AD</given-names></name>
<name><surname>Br&#x000e9;zin</surname><given-names>AP</given-names></name>
<name><surname>Nguyen</surname><given-names>QD</given-names></name>
<name><surname>Thorne</surname><given-names>JE</given-names></name>
<name><surname>Kestelyn</surname><given-names>P</given-names></name>
<etal/></person-group><article-title>Adalimumab in patients with active noninfectious uveitis</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>932</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">27602665</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>QD</given-names></name>
<name><surname>Merrill</surname><given-names>PT</given-names></name>
<name><surname>Jaffe</surname><given-names>GJ</given-names></name>
<name><surname>Dick</surname><given-names>AD</given-names></name>
<name><surname>Kurup</surname><given-names>SK</given-names></name>
<name><surname>Sheppard</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>1183</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">27542302</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suhler</surname><given-names>EB</given-names></name>
<name><surname>Ad&#x000e1;n</surname><given-names>A</given-names></name>
<name><surname>Br&#x000e9;zin</surname><given-names>AP</given-names></name>
<name><surname>Fortin</surname><given-names>E</given-names></name>
<name><surname>Goto</surname><given-names>H</given-names></name>
<name><surname>Jaffe</surname><given-names>GJ</given-names></name>
<etal/></person-group><article-title>Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III</article-title><source>Ophthalmology</source><year>2018</year><volume>125</volume><fpage>1075</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">29429764</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvo-R&#x000ed;o</surname><given-names>V</given-names></name>
<name><surname>Blanco</surname><given-names>R</given-names></name>
<name><surname>Beltr&#x000e1;n</surname><given-names>E</given-names></name>
<name><surname>S&#x000e1;nchez-Burs&#x000f3;n</surname><given-names>J</given-names></name>
<name><surname>Mesquida</surname><given-names>M</given-names></name>
<name><surname>Ad&#x000e1;n</surname><given-names>A</given-names></name>
<etal/></person-group><article-title>Anti-TNF-&#x003b1; therapy in patients with refractory uveitis due to Beh&#x000e7;et&#x02019;s disease: A 1-year follow-up study of 124 patients</article-title><source>Rheumatology</source><year>2014</year><volume>53</volume><fpage>2223</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24996907</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishikawa</surname><given-names>S</given-names></name>
<name><surname>Taguchi</surname><given-names>M</given-names></name>
<name><surname>Muraoka</surname><given-names>T</given-names></name>
<name><surname>Sakurai</surname><given-names>Y</given-names></name>
<name><surname>Kanda</surname><given-names>T</given-names></name>
<name><surname>Takeuchi</surname><given-names>M</given-names></name></person-group><article-title>Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Beh&#x000e7;et&#x02019;s disease</article-title><source>Br J Ophthalmol</source><year>2014</year><volume>98</volume><fpage>1508</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">24939422</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><article-title>The International Criteria for Beh&#x000e7;et&#x02019;s Disease: A collaborative study of 27 countries on the sensitivity and specificity of the new criteria</article-title><source>J Eur Acad Dermatol Venereol</source><year>2014</year><volume>28</volume><fpage>338</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">23441863</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jabs</surname><given-names>DA</given-names></name>
<name><surname>Nussenblatt</surname><given-names>RB</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JT</given-names></name>, <collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab></person-group><article-title>Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>3</volume><fpage>509</fpage><lpage>16</lpage></element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatemi</surname><given-names>G</given-names></name>
<name><surname>Christensen</surname><given-names>R</given-names></name>
<name><surname>Bang</surname><given-names>D</given-names></name>
<name><surname>Bodaghi</surname><given-names>B</given-names></name>
<name><surname>Celik</surname><given-names>AF</given-names></name>
<name><surname>Fortune</surname><given-names>F</given-names></name>
<etal/></person-group><article-title>2018 update of the EULAR recommendations for the management of Beh&#x000e7;et&#x02019;s syndrome</article-title><source>Ann Rheum Dis</source><year>2018</year><volume>77</volume><fpage>808</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">29625968</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takeuchi</surname><given-names>M</given-names></name>
<name><surname>Kezuka</surname><given-names>T</given-names></name>
<name><surname>Sugita</surname><given-names>S</given-names></name>
<name><surname>Keino</surname><given-names>H</given-names></name>
<name><surname>Namba</surname><given-names>K</given-names></name>
<name><surname>Kaburaki</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh&#x000e7;et&#x02019;s disease: A multicenter study</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><fpage>1877</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">24950593</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tugal-Tutkun</surname><given-names>I</given-names></name>
<name><surname>Mudun</surname><given-names>A</given-names></name>
<name><surname>Urgancioglu</surname><given-names>M</given-names></name>
<name><surname>Kamali</surname><given-names>S</given-names></name>
<name><surname>Kasapoglu</surname><given-names>E</given-names></name>
<name><surname>Inanc</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh&#x000e7;et&#x02019;s disease: An open-label trial</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>2478</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16052571</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bawazeer</surname><given-names>A</given-names></name>
<name><surname>Raffa</surname><given-names>LH</given-names></name>
<name><surname>Nizamuddin</surname><given-names>SH</given-names></name></person-group><article-title>Clinical experience with adalimumab in the treatment of ocular Beh&#x000e7;et disease</article-title><source>Ocular Immunol Inflamm</source><year>2010</year><volume>18</volume><fpage>226</fpage><lpage>32</lpage></element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fabiani</surname><given-names>C</given-names></name>
<name><surname>Sota</surname><given-names>J</given-names></name>
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Emmi</surname><given-names>G</given-names></name>
<name><surname>Vannozzi</surname><given-names>L</given-names></name>
<name><surname>Bacherini</surname><given-names>D</given-names></name>
<etal/></person-group><article-title>Ten-year retention rate of infliximab in patients with Beh&#x000e7;et&#x02019;s disease-related uveitis</article-title><source>Ocular Immunol Inflamm</source><year>2019</year><volume>27</volume><fpage>34</fpage><lpage>9</lpage></element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S</given-names></name>
<name><surname>Huang</surname><given-names>Z</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Beh&#x000e7;et&#x02019;s uveitis with vasculitis</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>93</volume><fpage>107430</fpage><comment>doi: 10.1016/j.intimp. 2021.107430</comment><pub-id pub-id-type="pmid">33581500</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fabiani</surname><given-names>C</given-names></name>
<name><surname>Sota</surname><given-names>J</given-names></name>
<name><surname>Vitale</surname><given-names>A</given-names></name>
<name><surname>Rigante</surname><given-names>D</given-names></name>
<name><surname>Emmi</surname><given-names>G</given-names></name>
<name><surname>Vannozzi</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Cumulative retention rate of adalimumab in patients with Beh&#x000e7;et&#x02019;s disease-related uveitis: A four-year follow-up study</article-title><source>Br J Ophthalmol</source><year>2018</year><volume>102</volume><fpage>637</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">28844047</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atienza-Mateo</surname><given-names>B</given-names></name>
<name><surname>Mart&#x000ed;n-Varillas</surname><given-names>JL</given-names></name>
<name><surname>Calvo-R&#x000ed;o</surname><given-names>V</given-names></name>
<name><surname>Demetrio-Pablo</surname><given-names>R</given-names></name>
<name><surname>Beltr&#x000e1;n</surname><given-names>E</given-names></name>
<name><surname>S&#x000e1;nchez-Burs&#x000f3;n</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>FRI0269 Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh&#x000e7;et&#x02019;s disease. National multicenter study of 177 cases</article-title><source>Ann Rheum Dis</source><year>2019</year><volume>78</volume><fpage>814</fpage><lpage>5</lpage></element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bejerano</surname><given-names>C</given-names></name>
<name><surname>Blanco</surname><given-names>R</given-names></name>
<name><surname>Mesquida</surname><given-names>M</given-names></name>
<name><surname>Ad&#x000e1;n</surname><given-names>A</given-names></name>
<name><surname>Espinosa</surname><given-names>G</given-names></name>
<name><surname>Beltr&#x000e1;n</surname><given-names>E</given-names></name>
<etal/></person-group><article-title>FRI0213 Anti-TNF therapy in refractory uveitis of behcet&#x02019;s syndrome. A multicenter study of 63 patients</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>71</volume><fpage>386</fpage></element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maalouf</surname><given-names>G</given-names></name>
<name><surname>Andrillon</surname><given-names>A</given-names></name>
<name><surname>Leclercq</surname><given-names>M</given-names></name>
<name><surname>S&#x000e8;ve</surname><given-names>P</given-names></name>
<name><surname>Bielefeld</surname><given-names>P</given-names></name>
<name><surname>Gueudry</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: A multicenter study of 330 patients</article-title><source>Am J Ophthalmol</source><year>2022</year><volume>238</volume><fpage>173</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">35172172</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mushtaq</surname><given-names>B</given-names></name>
<name><surname>Saeed</surname><given-names>T</given-names></name>
<name><surname>Situnayake</surname><given-names>RD</given-names></name>
<name><surname>Murray</surname><given-names>PI</given-names></name></person-group><article-title>Adalimumab for sight-threatening uveitis in Beh&#x000e7;et&#x02019;s disease</article-title><source>Eye</source><year>2007</year><volume>21</volume><fpage>824</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16601736</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takase</surname><given-names>K</given-names></name>
<name><surname>Ohno</surname><given-names>S</given-names></name>
<name><surname>Ideguchi</surname><given-names>H</given-names></name>
<name><surname>Uchio</surname><given-names>E</given-names></name>
<name><surname>Takeno</surname><given-names>M</given-names></name>
<name><surname>Ishigatsubo</surname><given-names>Y</given-names></name></person-group><article-title>Successful switching to adalimumab in an infliximab-allergic patient with severe Beh&#x000e7;et disease-related uveitis</article-title><source>Rheumatol Int</source><year>2011</year><volume>31</volume><fpage>243</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19816689</pub-id>
</element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karube</surname><given-names>H</given-names></name>
<name><surname>Kamoi</surname><given-names>K</given-names></name>
<name><surname>Ohno-Matsui</surname><given-names>K</given-names></name></person-group><article-title>Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Beh&#x000e7;et&#x02019;s disease</article-title><source>Int Med Case Rep J</source><year>2016</year><volume>9</volume><fpage>301</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">27729816</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olivieri</surname><given-names>I</given-names></name>
<name><surname>Leccese</surname><given-names>P</given-names></name>
<name><surname>D&#x02019;Angelo</surname><given-names>S</given-names></name>
<name><surname>Padula</surname><given-names>A</given-names></name>
<name><surname>Nigro</surname><given-names>A</given-names></name>
<name><surname>Palazzi</surname><given-names>C</given-names></name>
<etal/></person-group><article-title>Efficacy of adalimumab in patients with Beh&#x000e7;et&#x02019;s disease unsuccessfully treated with infliximab</article-title><source>Clin Exp Rheumatol</source><year>2011</year><volume>29</volume><fpage>54</fpage><lpage>7</lpage></element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shirahama</surname><given-names>S</given-names></name>
<name><surname>Kaburaki</surname><given-names>T</given-names></name>
<name><surname>Nakahara</surname><given-names>H</given-names></name>
<name><surname>Tanaka</surname><given-names>R</given-names></name>
<name><surname>Komae</surname><given-names>K</given-names></name>
<name><surname>Fujino</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Beh&#x000e7;et&#x02019;s uveitis</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>8612</fpage><pub-id pub-id-type="pmid">31197217</pub-id>
</element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balbaba</surname><given-names>M</given-names></name>
<name><surname>Ula&#x0015f;</surname><given-names>F</given-names></name>
<name><surname>Postac&#x00131;</surname><given-names>SA</given-names></name>
<name><surname>&#x000c7;eliker</surname><given-names>&#x000dc;</given-names></name>
<name><surname>G&#x000fc;rg&#x000f6;ze</surname><given-names>MK</given-names></name></person-group><article-title>Clinical and demographic features of pediatric-onset Beh&#x000e7;et&#x02019;s disease and evaluation of optical coherence tomography findings</article-title><source>Ocular Immunol Inflamm</source><year>2020</year><volume>28</volume><fpage>606</fpage><lpage>12</lpage></element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseini</surname><given-names>SM</given-names></name>
<name><surname>Morrovatdar</surname><given-names>N</given-names></name>
<name><surname>Hemati</surname><given-names>A</given-names></name>
<name><surname>Dolatkhah</surname><given-names>M</given-names></name>
<name><surname>Bakhtiari</surname><given-names>E</given-names></name>
<name><surname>Mirfeizi</surname><given-names>Z</given-names></name>
<etal/></person-group><article-title>Evaluation and comparison of choroidal thickness in patients with Beh&#x000e7;et disease with versus without ocular involvement</article-title><source>J Ophthalmic Vis Res</source><year>2021</year><volume>16</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">34055257</pub-id>
</element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>M</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Kwon</surname><given-names>HJ</given-names></name>
<name><surname>Kim</surname><given-names>SS</given-names></name>
<name><surname>Koh</surname><given-names>HJ</given-names></name>
<name><surname>Lee</surname><given-names>SC</given-names></name></person-group><article-title>Choroidal thickness in Behcet&#x02019;s uveitis: An enhanced depth imaging-optical coherence tomography and its association with angiographic changes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><fpage>6033</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23900605</pub-id>
</element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>UC</given-names></name>
<name><surname>Cho</surname><given-names>IH</given-names></name>
<name><surname>Moon</surname><given-names>SW</given-names></name>
<name><surname>Yu</surname><given-names>HG</given-names></name></person-group><article-title>Long-term change of subfoveal choroidal thickness in Beh&#x000e7;et&#x02019;s disease patients with posterior uveitis</article-title><source>Ocular Immunol Inflamm</source><year>2018</year><volume>26</volume><fpage>397</fpage><lpage>405</lpage></element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishikawa</surname><given-names>S</given-names></name>
<name><surname>Taguchi</surname><given-names>M</given-names></name>
<name><surname>Muraoka</surname><given-names>T</given-names></name>
<name><surname>Sakurai</surname><given-names>Y</given-names></name>
<name><surname>Kanda</surname><given-names>T</given-names></name>
<name><surname>Takeuchi</surname><given-names>M</given-names></name></person-group><article-title>Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Beh&#x000e7;et&#x02019;s disease</article-title><source>Br J Ophthalmol</source><year>2014</year><volume>98</volume><fpage>1508</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">24939422</pub-id>
</element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cordero-Coma</surname><given-names>M</given-names></name>
<name><surname>Sobrin</surname><given-names>L</given-names></name></person-group><article-title>Anti-tumor necrosis factor-&#x003b1; therapy in uveitis</article-title><source>Surv Ophthalmol</source><year>2015</year><volume>60</volume><fpage>575</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">26164735</pub-id>
</element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tugal-Tutkun</surname><given-names>I</given-names></name></person-group><article-title>Beh&#x000e7;et&#x02019;s uveitis</article-title><source>Middle East Afr J Ophthalmol</source><year>2009</year><volume>16</volume><fpage>219</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20404988</pub-id>
</element-citation></ref></ref-list></back></article>